B.A. in Economics, Indiana University
PhD in Economics, Stanford University
- national and international health policy issues related to insurance, pricing, and reimbursement
- economic evaluation of pharmaceuticals and diagnostics, particularly for organ transplantation, renal disease, influenza, and cancer
- PHARM 500: Quantative Methods I
- Pharm 532: Pharmacy Policy Methods
For the past 12 years, he worked as an economist in the pharmaceutical industry. Most recently, he was Vice President and Head of Health Economics & Strategic Pricing at Roche Pharmaceuticals, and was based in Basel, Switzerland from 2002 to 2004. The department had staff members located in Basel and Nutley, New Jersey, who were responsible for global health economic, pricing, and epidemiological strategies and analyses for new compounds from very early in development up to final preparation for launch. He oversaw the work of the managers who develop the economic strategies and research plans for all Roche compounds in development.
In 1992, Dr. Garrison joined Syntex Corporation as Director of Health Economics in Palo Alto, California. He managed Syntex's pharmacoeconomic research program for the development of mycophenolate mofetil for use in organ transplantation. After Roche acquired Syntex in 1995 through May, 2004, he was a manager and health economist in Roche's global health economics and outcomes group. Prior to this, he was Director of the Project HOPE Center for Health Affairs in Chevy Chase, Maryland. In eight years there, he worked on a wide variety of health policy issues. His research focused on the impact of technological change on health care costs. He also conducted studies of health care reform both in the U.S. and overseas. Before this, he worked at the Battelle Human Affairs Research Centers in Seattle, where he carried out studies of the adequacy of physician manpower supply and the cost-effectiveness of kidney and heart transplantation.